Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease

Cardioprotective effect of metformin in lipopolysaccharide-induced sepsis via suppression of toll-like receptor 4 (TLR4) in heart

(2016) Haleh Vaez et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca2+–XO–ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways

(2016) Ying Zhang et al.   FREE RADICAL BIOLOGY AND MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glucagon-like peptide-1 regulates calcium homeostasis and electrophysiological activities of HL-1 cardiomyocytes

(2016) Jen-Hung Huang et al.   PEPTIDES

The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin

(2016) Zahra Kashi et al.   PLoS One

Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

(2015) Wei Ren Chen et al.   AMERICAN HEART JOURNAL

GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats

(2015) Tomoaki Inoue et al.   ATHEROSCLEROSIS

Neuropharmacological Actions of Metformin in Stroke

(2015) Jia Jia et al.   Current Neuropharmacology

Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants

(2015) Marie-France Hivert et al.   DIABETES

Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes

(2015) Tao Xu et al.   DIABETES CARE

Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke

(2015) J. S. Floyd et al.   DIABETES OBESITY & METABOLISM

Interaction between metformin and leucine in reducing hyperlipidemia and hepatic lipid accumulation in diet-induced obese mice

(2015) Lizhi Fu et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Metformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose production in rats

(2015) Frank A Duca et al.   NATURE MEDICINE

Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis

(2015) Takeyuki Hiramatsu et al.   THERAPEUTIC APHERESIS AND DIALYSIS

Liraglutide and obesity: a review of the data so far

(2015) Ellen Ladenheim   Drug Design Development and Therapy

Incretin actions beyond the pancreas: lessons from knockout mice

(2013) Daisuke Yabe et al.   CURRENT OPINION IN PHARMACOLOGY

Do GLP-1-Based Therapies Increase Cancer Risk?

(2013) M. A. Nauck et al.   DIABETES CARE

Variants of NLRP3 gene are associated with insulin resistance in Chinese Han population with type-2 diabetes

(2013) Yingying Zheng et al.   GENE

Power failure: why small sample size undermines the reliability of neuroscience

(2013) Katherine S. Button et al.   NATURE REVIEWS NEUROSCIENCE

The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells

(2012) Aya Shiraki et al.   ATHEROSCLEROSIS

Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function

(2012) T. Forst et al.   DIABETIC MEDICINE

Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation

(2011) Daisuke Yabe et al.   PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY

Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study

(2010) G A Garinis et al.   INTERNATIONAL JOURNAL OF OBESITY

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Liraglutide

(2009) Katherine F. Croom et al.   DRUGS

Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway

(2009) R. Kimura et al.   NEUROSCIENCE

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis

(2008) R. LOOMBA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE